Trends in the Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Commercially Insured Adults Aged <65 Years
Authors' conclusion
Annual claims for DME or VTDR and anti-VEGF injections increased whereas those for laser photocoagulation decreased among commercially insured adults with diabetes.
Study context
- Population
- Commercially insured adults aged 18–64 years with diabetes, continuously enrolled in fee-for-service insurance for 24 months, IBM MarketScan Database, 2009–2018
- Outcome
- Annual prevalence of patients with ≥1 claims for any DME, DME or VTDR, and anti-VEGF injections and laser photocoagulation; Average annual percent change (AAPC)
- Follow-up
- 2009-2018
Methodological detailsclaims database analysis, 10-year trend analysis
- Claims database analysis
- 10-year trend analysis
Main finding
As reported in the abstract
Annual prevalence · 2009 to 2018
Diabetic macular edema (DME) or vision-threatening diabetic retinopathy (VTDR) prevalence increased (2.1% to 3.4%)
AAPC 7.5%
P < 0.001
Any DME prevalence increased (0.7% to 2.6%)
AAPC 19.8%
P < 0.001
Observational data: associations, not effects.
Further findings
Annual claims for antivascular endothelial growth factor (anti-VEGF) injections · 2009 to 2018
- Increase, any DME
- 327%
- Increase, VTDR with DME
- 206%
Annual claims for laser photocoagulation · 2009 to 2018
- Change, any DME
- −68%
- Change, VTDR with DME
- −54%
- Change, VTDR without DME
- −62%
Original publication
Trends in the Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Commercially Insured Adults Aged <65 Years. Diabetes Care. Published 13 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →